Cardiol Therapeutics Inc Class A faces a challenging session as its stock slips.
Cardiol Therapeutics Inc Class A (CRDL.TO) is seeing a downturn today, with shares dropping by 4.40% to close at CA$1.74. This decline reflects the ongoing volatility in the biotech sector, especially for companies still navigating clinical trials and regulatory hurdles.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$192.50M
52W high
$2.33
52W low
$1.23
1W change
-6.29%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 265.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+265.9% Upside
Current Price
C$1.64
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
50.9%
Annualized
90-Day Vol
60.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.55 | C$1.30 – C$1.84 |
| 60 trading days | C$1.46 | C$1.14 – C$1.87 |
| 90 trading days | C$1.37 | C$1.01 – C$1.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should stay cautious as Cardiol Therapeutics deals with market pressures and the impact of its recent clinical developments.
Stock Down 4.40% Today
With a market cap of CA$209.8 million, Cardiol Therapeutics is feeling the heat in a tough market environment.
Bull case
The company has shown potential with its Phase II results for CardiolRx™, which could lead to future growth if it’s successfully commercialized.
Bear case
However, the absence of immediate positive news and the current market sentiment may continue to put pressure on the stock, making it a risky investment in the short term.
Current Market Performance
Cardiol Therapeutics has seen its stock price decrease by 4.40% today, closing at CA$1.74. This drop mirrors broader market trends affecting biotech stocks, particularly those dependent on clinical trial outcomes and regulatory approvals.
Factors Influencing the Decline
Despite some positive developments in earlier clinical trials, the lack of recent updates may have led to investor uncertainty. The company's market cap stands at CA$209.8 million, placing it in a volatile sector that requires close attention.
Looking Ahead
Investors should watch for upcoming announcements from Cardiol Therapeutics, especially regarding its clinical trials and potential partnerships. The recent drop in stock price might offer a buying opportunity for long-term investors if the company can show steady progress.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
